Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Ziftomenib Added to NCCN Clinical Practice Guidelines for NPM1-Mutant R/R AML

November 26th 2025

The NCCN guidelines for AML have been updated to include ziftomenib as a category 2A recommendation for NPM1-mutant, relapsed/refractory AML management.

FDA Grants Priority Review to Sonrotoclax for R/R Mantle Cell Lymphoma

November 26th 2025

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Dr Raab on Safety and Infection Prophylaxis With Daratumumab-Based Induction Regimens in Myeloma

November 25th 2025

Marc S. Raab, MD, outlines the safety profile of teclistamab plus Dara-VRd in newly diagnosed multiple myeloma from the MajesTEC-5 trial.

Dr Kline on Updated Efficacy Data With Tovorafenib in R/R Pediatric Low Grade Glioma

November 24th 2025

Cassie Kline, MD, MAS, discusses 3-year follow-up data with tovorafenib in patients with pediatric low-grade glioma from FIREFLY-1.

Dr Grommes on the Addition of Ibrutinib to R-MPV Induction in Newly Diagnosed PCNSL

November 24th 2025

Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.

Dr Schaff on a Phase 1 Study of Copanlisib Plus Ibrutinib in Relapsed/Refractory PCNSL

November 24th 2025

Lauren Shaff, MD, contextualizes results from a phase 1 study evaluating copanlisib plus ibrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Dr Nayak on Findings From the PROSPECT Trial of Tirabrutinib in Relapsed/Refractory PCNSL

November 24th 2025

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Dr de la Fuente on Safety Data With Vorasidenib Plus Temozolomide in IDH-Mutant Glioma

November 23rd 2025

Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.

Dr Kurz on the Efficacy and Safety of Lutetium Lu 177 Dotatate in Advanced Intracranial Meningioma

November 22nd 2025

Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.

Dr Lombardi on Phase 1 Data With Regorafenib Plus Temozolomide and CRT for Newly Diagnosed Glioblastoma

November 22nd 2025

Giuseppe Lombardi, MD, PhD, discusses data with regorafenib plus temozolomide and radiation in newly diagnosed, MGMT-methylated, IDH-wild-type glioblastoma.

Dr Hirbe on Long-Term Efficacy and Safety Outcomes With Mirdametinib in Symptomatic NF1-PN

November 22nd 2025

Angela C. Hirbe, MD, PhD, discusses long-term follow-up data from the phase 2b ReNeu trial evaluating mirdametinib in patients with NF1-associated symptomatic PN.

Dr Jakubowiak on the Design of the Phase 3 ATLAS Trial in Multiple Myeloma

November 21st 2025

Andrzej Jakubowiak, MD, PhD, discusses the design of the phase 3 ATLAS trial in patients with newly diagnosed multiple myeloma after ASCT.

Dr Randall on the Goals and Methods of Prospective Research on Disparities in Sarcoma Survivorship

November 20th 2025

R. Lor Randall, MD, FACS, outlines the aims and phases of a prospective study evaluating outcome disparities in pediatric sarcoma survivorship care.

Beyond the Biopsy: A New Blood Test Is Redefining the Fight Against Relapsed AML

November 19th 2025

Liquid biopsy offers a revolutionary approach for detecting relapse in AML patients post-stem cell transplant, potentially enhancing early intervention.

Genomic, Immune, Epigenetic Features Drive Treatment Decision-Making in High-Risk NSCLC Subtypes

November 19th 2025

Benjamin Herzberg, MD discusses challenges and evolving strategies for managing high-risk NSCLC subsets, underscoring the value of genomic testing.

Giredestrant Becomes First Oral SERD to Show iDFS Benefit As Adjuvant Therapy in Early ER+, HER2-Negative Breast Cancer

November 18th 2025

The phase 3 lidERA trial shows improved iDFS with giredestrant vs standard therapy in early ER-positive, HER2-negative breast cancer.

FDA Grants Fast Track Designation to DPTX3186 for Gastric Cancer

November 18th 2025

DPTX3186, a first-in-class oral condensate modulator, has received FDA fast track designation in gastric cancer.

Dr Raab on Patient Enrollment and the Design of the MajesTEC-5 Trial in NDMM

November 18th 2025

Marc S. Raab, MD, details the patient characteristics and design of the phase 2 MajesTEC-5 trial evaluating teclistamab in newly diagnosed multiple myeloma.

Newer Generations, Resistance Profiling, and Toxicity Trade-offs Guide Modern TKI Selection/Use in Oncogene-Driven NSCLC

November 18th 2025

Alexander Drilon, MD, summarized approaches to TKI selection in NSCLC displaying oncogenic driver alterations for both TKI-pretreated and -naive patient populations.

FDA Approval of Lurbinectedin/Atezolizumab As First-Line Maintenance Expands Limited Post-Induction Arsenal for ES-SCLC

November 18th 2025

Joshua K. Sabari, MD, discusses the FDA approval of lurbinectedin plus atezolizumab as first-line maintenance therapy in extensive-stage SCLC.